184 related articles for article (PubMed ID: 11678784)
1. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
Sathyan G; Chancellor MB; Gupta SK
Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Gupta SK; Sathyan G
J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
4. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
Preik M; Albrecht D; O'Connell M; Hampel C; Anderson R
BJU Int; 2004 Oct; 94(6):821-7. PubMed ID: 15476516
[TBL] [Abstract][Full Text] [Related]
5. Extended-release oxybutynin.
Comer AM; Goa KL
Drugs Aging; 2000 Feb; 16(2):149-55; discussion 156-7. PubMed ID: 10755330
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline.
Gupta SK; Shah JC; Hwang SS
Br J Clin Pharmacol; 1999 Jul; 48(1):71-8. PubMed ID: 10383563
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
Chancellor MB; Appell RA; Sathyan G; Gupta SK
Clin Ther; 2001 May; 23(5):753-60. PubMed ID: 11394733
[TBL] [Abstract][Full Text] [Related]
8. Oxybutynin extended-release: a review of its use in the management of overactive bladder.
Siddiqui MA; Perry CM; Scott LJ
Drugs; 2004; 64(8):885-912. PubMed ID: 15059046
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the bioavailability of oxybutynin from a controlled release tablet.
Lukkari E; Castrèn-Kortekangas P; Juhakoski A; Löyttyniemi E; Aranko K; Neuvonen PJ
Eur J Clin Pharmacol; 1996; 50(3):221-3. PubMed ID: 8737763
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.
Sathyan G; Hu W; Gupta SK
J Clin Pharmacol; 2001 Feb; 41(2):187-92. PubMed ID: 11210400
[TBL] [Abstract][Full Text] [Related]
11. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite.
Lukkari E; Juhakoski A; Aranko K; Neuvonen PJ
Eur J Clin Pharmacol; 1997; 52(5):403-6. PubMed ID: 9272412
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Reiz JL; Salem P; Darke AC
J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
16. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
Versi E; Appell R; Mobley D; Patton W; Saltzstein D
Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
[TBL] [Abstract][Full Text] [Related]
17. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet.
Lukkari E; Aranko K; Juhakoski A; Hakonen T; Neuvonen PJ
Pharmacol Toxicol; 1997 Jul; 81(1):31-4. PubMed ID: 9258982
[TBL] [Abstract][Full Text] [Related]
18. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Goldenberg MM
Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
Mizushima H; Kinoshita K; Abe K; Ishizuka H; Yamada Y
Biol Pharm Bull; 2007 May; 30(5):955-62. PubMed ID: 17473442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
